Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease.

Badimon L., Oñate B., Vilahur G.

Clinical Trial on Cardiovascular Disease, Immune Modulation, published in Rev Esp Cardiol (Engl Ed) (2015) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Rev Esp Cardiol (Engl Ed) (2015)
Country
Spain
Reported sample size
—
Source database
PubMed
PMID
26028258
DOI
10.1016/j.rec.2015.02.025
Citations
40

Abstract (original English)

Adipose tissue has long been considered an energy storage and endocrine organ; however, in recent decades, this tissue has also been considered an abundant source of mesenchymal cells. Adipose-derived stem cells are easily obtained, show a strong capacity for ex vivo expansion and differentiation to other cell types, release a large variety of angiogenic factors, and have immunomodulatory properties. Thus, adipose tissue is currently the focus of considerable interest in the field of regenerative medicine. In the context of coronary heart disease, numerous experimental studies have supported the safety and efficacy of adipose-derived stem cells in the setting of myocardial infarction. These results have encouraged the clinical use of these stem cells, possibly prematurely. Indeed, the presence of cardiovascular risk factors, such as hypertension, coronary disease, diabetes mellitus, and obesity, alter and reduce the functionality of adipose-derived stem cells, putting in doubt the efficacy of their autologous implantation. In the present article, white adipose tissue is described, the stem cells found in this tissue are characterized, and the use of these cells is discussed according to the preclinical and clinical trials performed so far.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipocytes, WhiteAdipogenesisAdipokinesAdipose Tissue, WhiteAnimalsAntigens, CDBiomarkersClinical Trials as TopicDisease Models, AnimalHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research